• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用由中间向两端推进的方法对影响先天性肾上腺皮质增生症患者氢化可的松药代动力学的成熟过程的见解。

Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach.

作者信息

Michelet Robin, Bindellini Davide, Melin Johanna, Neumann Uta, Blankenstein Oliver, Huisinga Wilhelm, Johnson Trevor N, Whitaker Martin J, Ross Richard, Kloft Charlotte

机构信息

Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.

Graduate Research Training Program, Berlin, Germany.

出版信息

Front Pharmacol. 2023 Jan 12;13:1090554. doi: 10.3389/fphar.2022.1090554. eCollection 2022.

DOI:10.3389/fphar.2022.1090554
PMID:36712688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9877293/
Abstract

Hydrocortisone is the standard of care in cortisol replacement therapy for congenital adrenal hyperplasia patients. Challenges in mimicking cortisol circadian rhythm and dosing individualization can be overcome by the support of mathematical modelling. Previously, a non-linear mixed-effects (NLME) model was developed based on clinical hydrocortisone pharmacokinetic (PK) pediatric and adult data. Additionally, a physiologically-based pharmacokinetic (PBPK) model was developed for adults and a pediatric model was obtained using maturation functions for relevant processes. In this work, a middle-out approach was applied. The aim was to investigate whether PBPK-derived maturation functions could provide a better description of hydrocortisone PK inter-individual variability when implemented in the NLME framework, with the goal of providing better individual predictions towards precision dosing at the patient level. Hydrocortisone PK data from 24 adrenal insufficiency pediatric patients and 30 adult healthy volunteers were used for NLME model development, while the PBPK model and maturation functions of clearance and cortisol binding globulin (CBG) were developed based on previous studies published in the literature. Clearance (CL) estimates from both approaches were similar for children older than 1 year (CL/F increasing from around 150 L/h to 500 L/h), while CBG concentrations differed across the whole age range (CBG stable around 0.5 μM vs. steady increase from 0.35 to 0.8 μM for CBG ). PBPK-derived maturation functions were subsequently included in the NLME model. After inclusion of the maturation functions, none, a part of, or all parameters were re-estimated. However, the inclusion of CL and/or CBG maturation functions in the NLME model did not result in improved model performance for the CL maturation function (ΔOFV > -15.36) and the re-estimation of parameters using the CBG maturation function most often led to unstable models or individual CL prediction bias. Three explanations for the observed discrepancies could be postulated, i) non-considered maturation of processes such as absorption or first-pass effect, ii) lack of patients between 1 and 12 months, iii) lack of correction of PBPK CL maturation functions derived from urinary concentration ratio data for the renal function relative to adults. These should be investigated in the future to determine how NLME and PBPK methods can work towards deriving insights into pediatric hydrocortisone PK.

摘要

氢化可的松是先天性肾上腺皮质增生症患者皮质醇替代疗法的标准治疗药物。通过数学建模的支持,可以克服模拟皮质醇昼夜节律和给药个体化方面的挑战。此前,基于氢化可的松临床药代动力学(PK)的儿科和成人数据建立了非线性混合效应(NLME)模型。此外,还为成人建立了基于生理的药代动力学(PBPK)模型,并使用相关过程的成熟函数获得了儿科模型。在这项工作中,采用了由中间向外的方法。目的是研究在NLME框架中实施时,PBPK衍生的成熟函数是否能更好地描述氢化可的松PK的个体间变异性,目标是在患者层面为精准给药提供更好的个体预测。24名肾上腺功能不全儿科患者和30名成年健康志愿者的氢化可的松PK数据用于NLME模型开发,而PBPK模型以及清除率和皮质醇结合球蛋白(CBG)的成熟函数则基于文献中发表的先前研究建立。对于1岁以上儿童,两种方法得出的清除率(CL)估计值相似(CL/F从约150 L/h增加到500 L/h),而在整个年龄范围内CBG浓度有所不同(CBG稳定在约0.5 μM,而CBG从0.35 μM稳定增加到0.8 μM)。随后将PBPK衍生的成熟函数纳入NLME模型。纳入成熟函数后,对无、部分或所有参数进行了重新估计。然而,在NLME模型中纳入CL和/或CBG成熟函数并未改善CL成熟函数的模型性能(ΔOFV > -15.36),并且使用CBG成熟函数重新估计参数最常导致模型不稳定或个体CL预测偏差。对于观察到的差异,可以提出三种解释:i)未考虑吸收或首过效应等过程的成熟;ii)缺乏1至12个月大的患者;iii)未对从尿浓度比数据得出的PBPK CL成熟函数相对于成人的肾功能进行校正。未来应研究这些问题,以确定NLME和PBPK方法如何共同深入了解儿科氢化可的松PK。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/1b4f43f19d33/fphar-13-1090554-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/98d22c36921c/fphar-13-1090554-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/7e384514d783/fphar-13-1090554-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/55a482f909a8/fphar-13-1090554-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/34909c375e13/fphar-13-1090554-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/b1104443b420/fphar-13-1090554-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/5b1e5d4b4d11/fphar-13-1090554-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/63871693432b/fphar-13-1090554-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/5fbf698a3043/fphar-13-1090554-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/1b4f43f19d33/fphar-13-1090554-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/98d22c36921c/fphar-13-1090554-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/7e384514d783/fphar-13-1090554-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/55a482f909a8/fphar-13-1090554-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/34909c375e13/fphar-13-1090554-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/b1104443b420/fphar-13-1090554-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/5b1e5d4b4d11/fphar-13-1090554-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/63871693432b/fphar-13-1090554-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/5fbf698a3043/fphar-13-1090554-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c585/9877293/1b4f43f19d33/fphar-13-1090554-g009.jpg

相似文献

1
Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach.采用由中间向两端推进的方法对影响先天性肾上腺皮质增生症患者氢化可的松药代动力学的成熟过程的见解。
Front Pharmacol. 2023 Jan 12;13:1090554. doi: 10.3389/fphar.2022.1090554. eCollection 2022.
2
Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency.建立和验证皮质醇缺乏儿童和成人内源 PBPK 模型以指导氢化可的松替代治疗剂量。
Eur J Pharm Sci. 2021 Oct 1;165:105913. doi: 10.1016/j.ejps.2021.105913. Epub 2021 Jun 17.
3
The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing.皮质类固醇结合球蛋白的昼夜节律对氢化可的松给药后皮质醇暴露的影响很小。
Clin Endocrinol (Oxf). 2019 Jul;91(1):33-40. doi: 10.1111/cen.13969. Epub 2019 Apr 9.
4
Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.儿童先天性肾上腺皮质增生症患者氢化可的松治疗的药代动力学/药效学评价。
J Clin Endocrinol Metab. 2020 Mar 1;105(3). doi: 10.1210/clinem/dgaa071.
5
Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach.探索奥希替尼的种族间和患者间变异性及最佳剂量:基于生理学的药代动力学建模方法。
Front Pharmacol. 2024 Mar 4;15:1363259. doi: 10.3389/fphar.2024.1363259. eCollection 2024.
6
Pharmacokinetic Modeling of Hydrocortisone by Including Protein Binding to Corticosteroid-Binding Globulin.通过纳入与皮质类固醇结合球蛋白的蛋白质结合来进行氢化可的松的药代动力学建模。
Pharmaceutics. 2022 May 30;14(6):1161. doi: 10.3390/pharmaceutics14061161.
7
Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets.目前市售氢化可的松片剂治疗肾上腺功能不全疗效欠佳的药代动力学证据。
Clin Pharmacokinet. 2010 Jul;49(7):455-63. doi: 10.2165/11531290-000000000-00000.
8
Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis.探索干血斑皮质醇浓度作为监测儿科肾上腺皮质功能不全患者的替代方法:基于模型的分析
Front Pharmacol. 2022 Mar 17;13:819590. doi: 10.3389/fphar.2022.819590. eCollection 2022.
9
Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim.使用PK-Sim对儿科人群单克隆抗体进行基于生理的药代动力学建模。
Front Pharmacol. 2020 Jun 11;11:868. doi: 10.3389/fphar.2020.00868. eCollection 2020.
10
Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.PK-Sim®儿科模块用于 CYP450 代谢化合物的儿科暴露评估的模型验证。
J Toxicol Environ Health A. 2019;82(14):789-814. doi: 10.1080/15287394.2019.1652215. Epub 2019 Aug 12.

引用本文的文献

1
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy.一个用于理解下丘脑-垂体-肾上腺轴生理学及其与皮质醇替代治疗相互作用的定量建模框架。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):809-824. doi: 10.1007/s10928-024-09934-7. Epub 2024 Jul 8.
2
Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data.致力于伏立康唑的模型指导下精准给药:用真实世界临床数据挑战已发表的伏立康唑非线性混合效应模型。
Clin Pharmacokinet. 2023 Oct;62(10):1461-1477. doi: 10.1007/s40262-023-01274-y. Epub 2023 Aug 21.

本文引用的文献

1
Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency.建立和验证皮质醇缺乏儿童和成人内源 PBPK 模型以指导氢化可的松替代治疗剂量。
Eur J Pharm Sci. 2021 Oct 1;165:105913. doi: 10.1016/j.ejps.2021.105913. Epub 2021 Jun 17.
2
Evaluation of bias in weighted residual calculations when handling below the limit of quantification data using Beal's M3 method.使用比尔M3方法处理低于定量限数据时加权残差计算中的偏差评估。
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):275-278. doi: 10.1002/psp4.12616.
3
Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations.
数字健康时代模型驱动的精准给药展望:挑战、机遇与建议
Clin Pharmacol Ther. 2021 Jan;109(1):29-36. doi: 10.1002/cpt.2049. Epub 2020 Oct 17.
4
Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children.儿科人群药代动力学模型评估婴幼儿氢化可的松替代治疗剂量方案。
Eur J Endocrinol. 2020 Oct;183(4):357-368. doi: 10.1530/EJE-20-0231.
5
Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia.儿童先天性肾上腺皮质增生症患者氢化可的松治疗的药代动力学/药效学评价。
J Clin Endocrinol Metab. 2020 Mar 1;105(3). doi: 10.1210/clinem/dgaa071.
6
The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing.皮质类固醇结合球蛋白的昼夜节律对氢化可的松给药后皮质醇暴露的影响很小。
Clin Endocrinol (Oxf). 2019 Jul;91(1):33-40. doi: 10.1111/cen.13969. Epub 2019 Apr 9.
7
The use of PBPK modeling across the pediatric age range using propofol as a case.以丙泊酚为例,在儿科年龄范围内使用 PBPK 模型。
J Pharmacokinet Pharmacodyn. 2018 Dec;45(6):765-785. doi: 10.1007/s10928-018-9607-8. Epub 2018 Oct 8.
8
Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.儿科药物开发中的药代动力学-药效学建模,以及标准化清除率缩放的重要性。
Clin Pharmacokinet. 2019 Jan;58(1):39-52. doi: 10.1007/s40262-018-0659-0.
9
Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia.先天性肾上腺皮质增生症患者疾病、应激剂量和疾病后遗症的纵向评估。
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2336-2345. doi: 10.1210/jc.2018-00208.
10
PBPK in Preterm and Term Neonates: A Review.早产儿和足月新生儿的 PBPK:综述。
Curr Pharm Des. 2017;23(38):5943-5954. doi: 10.2174/1381612823666171009143840.